Injectable magnesium oxychloride cement foam (mocf)-derived scaffold for treating osteoporotic bone defects
US-2024108785-A1 · Apr 4, 2024 · US
US10052350B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10052350-B2 |
| Application number | US-201214344011-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 17, 2012 |
| Priority date | Sep 16, 2011 |
| Publication date | Aug 21, 2018 |
| Grant date | Aug 21, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides a corneal endothelial composition comprising a transparent hydrogel scaffold and a single layer of cultured corneal endothelial cells on the surface of the scaffold. The hydrogel scaffold I comprised of at least one biopolymer, preferably gelatin. Also provided are methods of making a corneal endothelial scaffold.
Opening claim text (preview).
What is claimed: 1. A corneal endothelial composition comprising a transparent hydrogel scaffold modified with heparin and a layer of corneal endothelial cells present on the surface of the hydrogel scaffold, wherein the hydrogel scaffold is modified with an amount of heparin that enhances proliferation of the corneal endothelial cells on the hydrogel scaffold; wherein the hydrogel scaffold comprises and is cross-linked with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), and N-hydroxysuccinimide (NHS); wherein the hydrogel scaffold comprises gelatin; and wherein the transparent hydrogel scaffold is formed by drying a solution comprising gelatin in a mold at room temperature. 2. The composition of claim 1 , wherein the hydrogel scaffold further comprises at least one synthetic polymer, wherein the synthetic polymer is selected from the group consisting of (meth)acrylate-oligolactide-PEO-oligolactide-(meth)acrylate, poly(ethylene glycol) (PEO), poly(propylene glycol) (PPO), PEO-PPO-PEO copolymers, poly(phosphazene), poly(methacrylates), poly(N-vinylpyrrolidone), PL(G)A-PEO-PL(G)A copolymers, poly(ethylene imine), and poly(ethyl glycol) diacrylate. 3. The composition of claim 1 , wherein gelatin is modified with methacrylic anhydride to form gelatin methacrylate. 4. The composition of claim 1 , wherein the corneal endothelial cells are obtained from donor cornea. 5. A method of making the corneal endothelial composition of claim 1 , the method comprising generating a thin hydrogel scaffold by drying a solution comprising gelatin in a mold at room temperature, adding both EDC and NHS to the hydrogel scaffold, crosslinking the hydrogel sheet with the EDC and NHS and culturing corneal endothelial cells on the surface of the hydrogel scaffold, wherein the hydrogel scaffold comprises heparin and is transparent. 6. The method of claim 5 , wherein the hydrogel scaffold further comprises at least one synthetic polymer, wherein the synthetic polymer is selected from the group consisting of (meth)acrylate-oligolactide-PEO-oligolactide-(meth)acrylate, poly(ethylene glycol) (PEO), poly(propylene glycol) (PPO), PEO-PPO-PEO copolymers (Pluronics), poly(phosphazene), poly(methacrylates), poly(N-vinylpyrrolidone), PL(G)A-PEO-PL(G)A copolymers, poly(ethylene imine), and poly(ethyl glycol) diacrylate. 7. The method of claim 5 , wherein the gelatin is modified with methacrylic anhydride to form gelatin methacrylate. 8. The method of claim 5 , wherein the corneal endothelial cells are obtained from donor cornea. 9. The method of claim 5 , wherein the corneal endothelial cells are cultured in the presence of basic fibroblast growth factor (bFGF). 10. The composition of claim 1 , wherein the composition has a size of about 10-90% of corneal endothelium. 11. The composition of claim 1 , wherein the hydrogel scaffold is in the range of about 100-300 μm thick. 12. A corneal endothelial composition comprising a transparent hydrogel scaffold modified with heparin and a layer of corneal endothelial cells present on the surface of the hydrogel scaffold, wherein the hydrogel scaffold comprises gelatin, is cross-linked with, 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), and N-hydroxysuccinimide (NHS), and wherein the hydrogel scaffold is modified with an amount of heparin that enhances proliferation of the corneal endothelial cells on the hydrogel scaffold; wherein the hydrogel scaffold comprises at least one synthetic polymer, wherein the synthetic polymer is selected from the group consisting of (meth)acrylate-oligolactide-PEO-oligolactide-(meth)acrylate, poly(ethylene glycol) (PEO), poly(propylene glycol) (PPO), PEO-PPO-PEO copolymers, poly(phosphazene), poly(methacrylates), poly(N-vinylpyrrolidone), PL(G)A-PEO-PL(G)A copolymers, poly(ethylene imine), and poly(ethyl glycol) diacrylate; and wherein the transparent hydrogel scaffold is formed by drying a solution comprising gelatin in a mold at room temperature.
Hydrogels or hydrocolloids · CPC title
Gelatin · CPC title
Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue · CPC title
Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof · CPC title
for reconstruction of eye parts, e.g. intraocular lens, cornea · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.